A Phase III, double-blind, placebo-controlled intervention trial, where Diamyd^® (GAD-alum) is administered directly into lymph nodes in adolescents and adults with recently diagnosed Type 1 Diabetes, carrying the genetic HLA DR3-DQ2 haplotype. The trial evaluates the effectiveness of preserving the insulin producing capacity. This trial is conducted in six countries: Sweden, Spain, Poland, Germany, the Czech Republic and the Netherlands .

• 330 participants
• 12 − 29 years
• 24 mth duration
• Diabetes Type 1

Norway: Norwegian University of Science and Technology in Trondheim (NTNU), in cooperation with St. Olav’s University Hospital, Trondheim.

Sweden: Academic Specialist Center, Center for Diabetes, Karolinska Institute, Karolinska University Hospital, Stockholm.

An open label investigator initiated clinical trial, where Diamyd^®(GAD-alum) is administered directly into lymph nodes with oral supplements of vitamin D. The purpose of the trial is to evaluate the safety of intralymphatic treatment with Diamyd^® in LADA patients and the effectiveness of preserving the insulin producing capacity. The trial is conducted in Norway and Sweden.

• 15
• 30 − 70 years
• 12 mth duration
• LADA

An open label investigator initiated intervention trial with oral treatment of Remygen^®. The aim of the trial is to evaluate the safety of the treatment and the effect on the ability to regenerate insulin-producing beta cells.

• 30 participants
• 18 − 50 years
• 9 mth duration
• Diabetes Type 1